David N Brindley holds a Ph.D. from the University of Birmingham, UK. He is currently a Professor of Biochemistry at the Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. He is also the Director of the Signal Transduction Research Group and the Co-Director of the Cancer Research Institute of Northern Alberta. His major research interest is to improve the treatment of breast cancer. He was a winner of the Fournier Pharma-CLC Award in Atherosclerosis Research Communication and the Brooks and District Diabetes Association Research Prize. He was also awarded the Academico Correspondiente of the Royal Academy of Pharmacy, Spain, the Senior Investigator of Alberta Heritage Foundation for Medical Research and more.